Enter your information to understand your Apolipoprotein A1 levels.

The History of ApoA1

The story of ApoA1 begins with physician and scientist John Gofman, who in the early 1950s at the University of California, Berkeley, used a high-speed ultracentrifuge to spin blood samples and separate fat-carrying particles by their density, discovering distinct classes that we now know as HDL and LDL cholesterol. It took until the 1960s and 1970s for protein chemistry techniques to advance enough for researchers to isolate and identify the individual protein components riding along inside these particles, revealing that one particular protein made up the vast majority of HDL's physical structure — the protein eventually named apolipoprotein A1, or ApoA1, once its full sequence and biological role were finally worked out in careful detail over many years of research.

What ApoA1 Actually Is

ApoA1 is the main structural protein of HDL particles, produced primarily by the liver and small intestine, and it does far more than simply hold the particle together as passive scaffolding. It actively activates an enzyme called LCAT, which chemically modifies cholesterol so it can be packed efficiently inside HDL for transport through the bloodstream, and it enables HDL's signature function known as reverse cholesterol transport — collecting excess cholesterol from artery walls and other tissues and ferrying it back to the liver, where it can finally be broken down and eliminated from the body entirely. This process is a major reason HDL is considered protective against cardiovascular disease, and ApoA1 is the specific protein that makes the entire mechanism mechanically possible in the first place, without which HDL could not function.

How ApoA1 Is Measured

ApoA1 is measured using immunoturbidimetric or immunonephelometric assays, in which antibodies specifically designed to bind ApoA1 are mixed directly with a patient's blood sample; as the antibodies latch onto the protein, they form tiny clusters that scatter light in a way an automated laboratory analyzer can precisely detect and quantify in real time. The amount of light scattering measured is directly proportional to how much ApoA1 protein is present in the original sample being tested. These assays are carefully calibrated against international reference standards set by organizations like the World Health Organization, keeping results broadly consistent across different laboratories, instruments, and manufacturers worldwide, year after year.

Scientists Behind the Science

John Gofman's pioneering ultracentrifugation work in the early 1950s created the entire conceptual framework of lipoprotein classification that all later ApoA1 research would eventually build upon, decades into the future. Biochemist Angelo Scanu spent much of his career through the 1960s and 1970s meticulously characterizing the detailed structure and behavior of apolipoproteins, including extensive work on ApoA1 itself, helping transform it from an obscure protein fragment into a well-understood, routinely tested clinical marker used worldwide. Separately, physician-scientist John Glomset proposed the reverse cholesterol transport hypothesis in 1968, giving researchers and clinicians a clear functional explanation for why higher ApoA1 levels correspond to lower cardiovascular risk — a concept that remains central to how doctors interpret cholesterol test results even today, more than fifty years after it was first proposed.